Personalized genetic and biomarker approach for ALS
Towards a PERsonalized MEdicine in Amyotrophic Lateral Sclerosis (ALS) by a Patient-tailored Genetic/Biomarker/iPSC Combined Approach - PERMEALS
A.O.U. Città della Salute e della Scienza · NCT06917924
This study is testing how genetic and biomarker information can help understand the differences in ALS for 200 newly diagnosed patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | A.O.U. Città della Salute e della Scienza (other) |
| Locations | 4 sites (Milan and 3 other locations) |
| Trial ID | NCT06917924 on ClinicalTrials.gov |
What this trial studies
This study aims to investigate the genetic and biomarker profiles of patients diagnosed with Amyotrophic Lateral Sclerosis (ALS) through a comprehensive approach. It will recruit 200 newly diagnosed ALS patients and perform genetic screening alongside biochemical and neuroradiological assessments to understand the disease's variability and progression. Patients will be classified based on specific ALS types and followed up regularly to monitor their clinical status and cognitive function. The study seeks to identify genetic variants that may influence ALS susceptibility and phenotypic differences.
Who should consider this trial
Good fit: Ideal candidates for this study are adults diagnosed with ALS, regardless of the specific type of the disease.
Not a fit: Patients under 18 years old will not benefit from this study as they are excluded from participation.
Why it matters
Potential benefit: If successful, this study could lead to more personalized treatment strategies for ALS patients based on their genetic and biomarker profiles.
How similar studies have performed: Other studies have shown promise in using genetic and biomarker approaches for ALS, indicating that this methodology has potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of ALS Exclusion Criteria: * ALS patients under 18 years old
Where this trial is running
Milan and 3 other locations
- IRCCS Istituto Auxologico Italiano — Milan, Italy (RECRUITING)
- Istituto di Ricerche Farmacologiche Mario Negri IRCCS — Milan, Italy (RECRUITING)
- Università degli Studi della Campania "Luigi Vanvitelli" — Naples, Italy (RECRUITING)
- AOU Citta della Salute e della Scienza di Torino — Torino, Italy (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Amyotrophic Lateral Sclerosis